Merck Property, Plant, and Equipment 2010-2024 | MRK

Merck property, plant, and equipment from 2010 to 2024. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
  • Merck property, plant, and equipment for the quarter ending September 30, 2024 was $23.446B, a 4.08% increase year-over-year.
  • Merck property, plant, and equipment for 2023 was $23.051B, a 7.6% increase from 2022.
  • Merck property, plant, and equipment for 2022 was $21.422B, a 11.12% increase from 2021.
  • Merck property, plant, and equipment for 2021 was $19.279B, a 13.41% increase from 2020.
Merck Annual Property, Plant, and Equipment
(Millions of US $)
2023 $23,051
2022 $21,422
2021 $19,279
2020 $17,000
2019 $15,053
2018 $13,291
2017 $12,439
2016 $12,026
2015 $12,507
2014 $13,136
2013 $14,973
2012 $16,030
2011 $16,297
2010 $17,082
2009 $18,279
Merck Quarterly Property, Plant, and Equipment
(Millions of US $)
2024-09-30 $23,446
2024-06-30 $23,221
2024-03-31 $23,045
2023-12-31 $23,051
2023-09-30 $22,526
2023-06-30 $22,231
2023-03-31 $21,758
2022-12-31 $21,422
2022-09-30 $20,424
2022-06-30 $20,059
2022-03-31 $19,747
2021-12-31 $19,279
2021-09-30 $18,565
2021-06-30 $18,064
2021-03-31 $18,295
2020-12-31 $17,000
2020-09-30 $16,919
2020-06-30 $15,789
2020-03-31 $15,269
2019-12-31 $15,053
2019-09-30 $14,287
2019-06-30 $13,862
2019-03-31 $13,506
2018-12-31 $13,291
2018-09-30 $12,755
2018-06-30 $12,626
2018-03-31 $12,561
2017-12-31 $12,439
2017-09-30 $12,189
2017-06-30 $12,094
2017-03-31 $12,042
2016-12-31 $12,026
2016-09-30 $12,029
2016-06-30 $11,987
2016-03-31 $12,360
2015-12-31 $12,507
2015-09-30 $12,482
2015-06-30 $12,630
2015-03-31 $12,910
2014-12-31 $13,136
2014-09-30 $13,438
2014-06-30 $13,893
2014-03-31 $14,296
2013-12-31 $14,973
2013-09-30 $15,323
2013-06-30 $15,683
2013-03-31 $15,802
2012-12-31 $16,030
2012-09-30 $15,884
2012-06-30 $15,867
2012-03-31 $16,124
2011-12-31 $16,297
2011-09-30 $16,383
2011-06-30 $16,671
2011-03-31 $16,833
2010-12-31 $17,082
2010-09-30 $17,116
2010-06-30 $17,334
2010-03-31 $17,985
2009-12-31 $18,279
2009-09-30 $11,614
2009-06-30 $11,711
2009-03-31 $11,826
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $244.211B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94